Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12607739 | 1.00 | ALDH1A1 (0.30) | ALDH1A1HPGDSMN1; SMN2CHRNB2CHRNA4 | |
| SCHEMBL14877786 | 1.00 | ALDH1A1 (0.30) | ALDH1A1HPGDSMN1; SMN2CHRNB2CHRNA4 | |
| SCHEMBL12607743 | 0.92 | ALDH1A1 (0.32) | ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL12607740 | 0.91 | GPR35 (0.33) | ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL12607748 | 0.87 | CHRNB2 (0.32) | ALDH1A1HPGDCHRNB2CHRNA4 | |
| SCHEMBL13626118 | 0.75 | — | — | |
| SCHEMBL12044730 | 0.75 | TMIGD3 (0.37) | ALDH1A1HPGD | |
| SCHEMBL13351651 | 0.75 | MAPK1 (0.30) | — | |
| SCHEMBL22789166 | 0.72 | ALDH1A1 (0.31) | ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL13363462 | 0.72 | RARG (0.35) | CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426424-B2 | Certain substituted amides, method of making, and method of use thereof | CGI PHARMACEUTICALS, INC. (US) | 2013-04-23 | — | — | US | disclosed |
| US-20110118233-A1 | Certain Substituted Amides, Method of Making, and Method of Use Thereof | CGI PHARMACEUTICALS, INC. | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118233-A1 | Certain Substituted Amides, Method of Making, and Method of Use Thereof | BTK, SYK, MYD88 | ALDH1A1 3393/4885HPGD 1470/4885SMN1; SMN2 3343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.